Immuneering Corp - Ordinary Shares Class A

NASDAQ:IMRX   3:59:51 PM EDT
25.91
+1.37 (+5.58%)
Products, Earnings Announcements

Immuneering To Present Preclinical Data At AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Published: 10/01/2021 11:18 GMT
Immuneering Corp - Ordinary Shares Class A (IMRX) - Immuneering to Present Preclinical Data at Aacr-nci-eortc International Conference on Molecular Targets and Cancer Therapeutics.
Immuneering Corp - Anticipates Submission of Investigational New Drug Application for Imm-1-104 to U.S. Food and Drug Administration in Q1 2022.
Immuneering - Data Shows Broad Antitumor Activity of Imm-1-104 Across Ras, Raf Mutant Tumors, Highlights Mechanistic Aspects of Dual Mek Inhibition.
Revenue is expected to be $0.7 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $0.72 Million
Next Quarter EPS Guidance is expected to be -$0.47

More details on our Analysts Page.